This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fox, E. Articles by Balis, F. M. Search for Related Content PubMed PubMed Citation Articles by Fox, E. Articles by Balis, F. M.

A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors

Authors' Affiliations: ¹ Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; ² Children's Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; ³ Children's Memorial Medical Center, Chicago, Illinois; and ⁴ Abbott Laboratories, Abbott Park, Illinois

Requests for reprints: Elizabeth Fox, Pediatric Oncology Branch, National Cancer Institute, Room 1-5750, Building 10-CRC, 10 Center Drive, Bethesda, MD 20892. Phone: 301-402-6641; Fax: 301-480-8871; E-mail: foxb{at}mail.nih.gov.

Purpose: To determine the toxicity profile, dose-limiting toxicities, and maximum tolerated dose of ABT-751 administered orally once daily for 7 days, repeated every 21 days.

Experimental Design: Patients who were 18 years of age, with relapsed or refractory solid tumors, and who were able to swallow capsules were eligible. The starting dose was 100 mg/m²/d (n = 3) and was escalated to 130 mg/m²/d (n = 6), 165 mg/m²/d (n = 6), 200 mg/m²/d (n = 6), and 250 mg/m²/d (n = 2) in cohorts of three to six patients. The maximum tolerated dose was determined from dose-limiting toxicities occurring during the first treatment cycle.

Results: Twenty-four children (median age, 13 years; range, 4-18 years) were enrolled; 23 were evaluable for toxicity. Diagnoses included neuroblastoma (n = 8), sarcomas (n = 8), primary brain tumors (n = 2), Wilms' tumor (n = 2), and other solid tumors (n = 3). Dose-limiting toxicities (grade 3 sensory and motor neuropathy, grade 3 hypertension, and grade 3 fatigue) were observed in patients enrolled at the 250 mg/m²/d dose level. The maximum tolerated dose of ABT-751 administered daily for 7 days every 21 days was 200 mg/m²/d. Non-dose-limiting toxicities at the maximum tolerated dose included anemia, fatigue, peripheral sensory neuropathy, abdominal pain, nausea, constipation, anorexia, fever, and weight loss. Myelosuppression was minimal at the maximum tolerated dose. The median number of cycles administered is 2 (range, 1-50). No significant ABT-751-related cumulative toxicities were observed.

Conclusion: ABT-751 is well tolerated in children. The recommended dose for phase 2 trials in solid tumors is 200 mg/m²/d administered orally, daily for 7 days every 21 days. This dose is >40% higher than the maximum tolerated dose in adults receiving the same dosing schedule.

This article has been cited by other articles:

				A. Kim, E. Fox, K. Warren, S. M. Blaney, S. L. Berg, P. C. Adamson, M. Libucha, E. Byrley, F. M. Balis, and B. C. Widemann Characteristics and Outcome of Pediatric Patients Enrolled in Phase I Oncology Trials Oncologist, June 1, 2008; 13(6): 679 - 689. [Abstract] [Full Text] [PDF]

				E. Fox, J. M. Maris, B. C. Widemann, W. Goodspeed, A. Goodwin, M. Kromplewski, M. E. Fouts, D. Medina, S. L. Cohn, A. Krivoshik, et al. A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors Clin. Cancer Res., February 15, 2008; 14(4): 1111 - 1115. [Abstract] [Full Text] [PDF]

				S. P. Newman, P. A. Foster, C. Stengel, J. M. Day, Y. T. Ho, J.-G. Judde, M. Lassalle, G. Prevost, M. P. Leese, B. V.L. Potter, et al. STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells Clin. Cancer Res., January 15, 2008; 14(2): 597 - 606. [Abstract] [Full Text] [PDF]

				J.-P. Liou, K.-S. Hsu, C.-C. Kuo, C.-Y. Chang, and J.-Y. Chang A Novel Oral Indoline-Sulfonamide Agent, N-[1-(4-Methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-Isonicotinamide (J30), Exhibits Potent Activity against Human Cancer Cells in Vitro and in Vivo through the Disruption of Microtubule J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 398 - 405. [Abstract] [Full Text] [PDF]